List of Nouress drug patents
Nouress is owned by Baxter Hlthcare Corp.
Nouress contains Cysteine Hydrochloride.
Nouress has a total of 12 drug patents out of which 0 drug patents have expired.
Nouress was authorised for market use on 13 December, 2019.
Nouress is available in solution;intravenous dosage forms.
Nouress can be used as method of intravenously administering a diluted cysteine hydrochloride solution to a neonate in need thereof, method of using l-cysteine in an admixture for treating patients needing parenteral nutrition.
The generics of Nouress are possible to be released after 15 March, 2039.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10583155 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
| US10933089 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
| US10918662 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
| US10905713 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
| US10912795 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
| US10653719 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
| US10478453 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
| US10905714 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
| US10493051 | BAXTER HLTHCARE CORP | Cysteine composition and injection |
Mar, 2039
(15 years from now) | |
| US10543186 | BAXTER HLTHCARE CORP | Cysteine composition and injection |
Mar, 2039
(15 years from now) | |
| US11045438 | BAXTER HLTHCARE CORP | Cysteine composition and injection |
Mar, 2039
(15 years from now) | |
| US10702490 | BAXTER HLTHCARE CORP | Cysteine composition and injection |
Mar, 2039
(15 years from now) | |
Drugs and Companies using CYSTEINE HYDROCHLORIDE ingredient
Market Authorisation Date: 13 December, 2019
Treatment: Method of using l-cysteine in an admixture for treating patients needing parenteral nutrition; Method of intravenously administering a diluted cysteine hydrochloride solution to a neonate in need thereof
Dosage: SOLUTION;INTRAVENOUS
NOURESS family patents
17
United States
1
Canada
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic